Selzentry Tablet, Film Coated
NDC Package 49702-224-18
Package Information
Selzentry (maraviroc) tablets is sELZENTRY is indicated in combination with other antiretroviral agents for the treatment of only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection in adult and pediatric patients weighing at least 2 kg.Limitations of Use•SELZENTRY is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 [see Microbiology (12.4)]. This formulation utilizes a tablet, film coated delivery system. Marketed by Viiv Healthcare Company, this product is identified by NDC 49702-224 and is authorized under FDA application NDA022128.
Identification & Billing
- RxCUI: 1857921 - maraviroc 20 MG in 1 mL Oral Solution
- RxCUI: 1857921 - maraviroc 20 MG/ML Oral Solution
- RxCUI: 1857921 - maraviroc 20 MG per 1 ML Oral Solution
- RxCUI: 1857925 - Selzentry 20 MG in 1 mL Oral Solution
- RxCUI: 1857925 - maraviroc 20 MG/ML Oral Solution [Selzentry]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 49702 - Viiv Healthcare Company
- 49702-224 - Selzentry
- 49702-224-18 - 60 TABLET, FILM COATED in 1 BOTTLE
- 49702-224 - Selzentry
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 49702-224-18 identifies a specific commercial package of 60 tablet, film coated in 1 bottle of Selzentry, a human prescription drug labeled by Viiv Healthcare Company. This tablet, film coated is formulated for oral use and contains maraviroc as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Viiv Healthcare Company on May 16, 2011. The current certification is valid through December 31, 2027.
How is this Viiv Healthcare Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 49702022418. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.